Exhibit 99.1


Navidea Biopharmaceuticals Reports Fourth Quarter 2022 Financial Results


Conference Call to be held Tuesday, March 21, 2023 at 5:00 pm (EDT)


DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the three-month and twelve-month periods ended December 31, 2022.


Fourth Quarter 2022 Highlights and Subsequent Events



Continued enrollment into the Company’s NAV3-33 Phase 3 trial in rheumatoid arthritis (“RA”) titled “Evaluation of Tc 99m Tilmanocept Imaging for the Early Prediction of Anti-TNFα Therapy Response in Patients with Moderate to Severe Active Rheumatoid Arthritis.” The Company announced enrollment of the 50th participant in NAV3-33 in November 2022.



Presented positive results from the Company’s completed NAV3-31 Phase 2B clinical study as well as the positive preliminary results of its ongoing NAV3-32 Phase 2B study at the Annual Meeting of the American College of Rheumatology held November 10-14, 2022 in Philadelphia, PA.



Presented results from the Company’s ongoing preclinical studies evaluating targeted immunotherapy for cancer based on the Manocept platform at the 37th Annual Meeting of the Society for Immunotherapy of Cancer held November 8-12, 2022 in Boston, MA. Results demonstrate efficacy of new constructs at macrophage phenotype change and in a mouse tumor model.



Received notification of issuance of U.S. Patent No. 11,590,236 from the United States Patent and Trademark Office for the Company’s application titled, “Compositions And Methods For Altering Macrophage Phenotype.” This patent covers the ability of the Company’s constructs to stimulate an immune response against tumors through targeted delivery of payloads that change the nature of macrophages to make them more proinflammatory. Efficacy of these constructs has been demonstrated in preclinical studies.



Received notifications of issuance for Company patent applications in the state of Israel for the application titled, “Compounds And Compositions For Treating Leishmaniasis And Methods Of Diagnosis And Treating Using Same” (State of Israel Patent No. 265830; U.S. counterpart application issued in June 2022 as U.S. Patent No. 11,369,680) and in Canada for Canadian Patent No. 2,955,441 titled, “Compositions, Methods, and Kits for Diagnosing and Treating CD206 Expressing Cell-Related Disorders.” (U.S. counterpart application issued in October 2020 as U.S. Patent No. 10,806,803.)



Filed a provisional patent application describing a different chemical linker used in a critical step in the Manocept synthesis process, one which is more stable and easier to manufacture than the current linker that is used. This could have significant implications for both diagnostic and therapeutic applications.





Converted several provisional patent applications to reviewable patent applications in the U.S. and Patent Cooperation Treaty countries.



The Company’s work performed in collaboration with investigators from the University of Alabama at Birmingham and titled, “In vivo Assessment of the Impact of Molecular Weight on Constructs of 68Ga-DOTA-Manocept in a Syngeneic Mouse Tumor Model” was published in the journal Molecular Imaging and Biology (2023 Mar. 7. Online ahead of print.).


Michael Rosol, Ph.D., Chief Medical Officer for Navidea, said, “The Phase 3 and Phase 2B trials in RA continue to enroll and advance towards completion. The company continues to work diligently to advance its technology in key disease areas, with an emphasis on our RA program. We are pleased with the preliminary positive results from the NAV3-32 study that thus far support our hypothesis that we can distinguish between fibroid and non-fibroid pathotypes of RA with a single scan.” Dr. Rosol continued, “Concurrent with all of this, we continue to make progress in our therapeutics pipeline, and we expect to keep advancing these towards IND filing and clinical trials. The promising results to date of our RA trials and the preclinical studies of our therapeutics demonstrate the significant potential of our macrophage-targeting Manocept platform.”


Financial Results



Total revenues for the three-month period ended December 31, 2022 were approximately $1,000, compared to $50,000 for the same period in 2021. Total revenues for the year ended December 31, 2022 were $66,000, compared to $532,000 for the same period in 2021. The decrease was primarily due to the 2021 partial recovery of debts previously written off in 2015, the 2021 receipt of reimbursement from Cardinal Health 414, LLC of certain research and development (“R&D”) costs, decreased grant revenue related to Small Business Innovation Research grants from the National Institutes of Health supporting Manocept development, and decreased license revenue from transitional sales of Tc99m tilmanocept in Europe.



Research and development expenses for the three-month period ended December 31, 2022 were $1.9 million, compared to $1.4 million for the same period in 2021. R&D expenses for the year ended December 31, 2022 were $6.0 million, compared to $5.1 million for the same period in 2021. The year-over-year increase was primarily due to increased drug project expenses and increased employee compensation including incentive-based awards, offset by decreased regulatory consulting expenses.



Selling, general and administrative (“SG&A”) expenses for the three-month period ended December 31, 2022 were $1.3 million, compared to $2.3 million for the same period in 2021. SG&A expenses for the year ended December 31, 2022 were $8.0 million, compared to $7.5 million for the same period in 2021. Following the ruling by the Texas Court in August 2022, the Company recorded $2.6 million of legal fees in SG&A pursuant to the CRG judgment. The year-over-year increase was also due to increases in insurance and depreciation and amortization, partially offset by decreases in employee compensation including fringe benefits and incentive-based awards, expenses related to European operations, travel, legal and professional services, investor relations and shareholder services, general office expenses, facilities costs, losses on the abandonment of certain intellectual property and franchise taxes.





Navidea’s net loss attributable to common stockholders for the three-month period ended December 31, 2022 was $3.5 million, or $0.11 per share, compared to $3.7 million, or $0.12 per share, for the same period in 2021. Navidea’s net loss attributable to common stockholders for the year ended December 31, 2022 was $17.2 million, or $0.56 per share, compared to $11.7 million, or $0.40 per share, for the same period in 2021.



Navidea ended the fourth quarter of 2022 with approximately $2.0 million in cash and cash equivalents.


Conference Call Details


Investors and the public are invited to dial into the earnings call through the information listed below, or participate via the audio webcast on the company website. Dr. Michael Rosol, Chief Medical Officer, and Erika Eves, Vice President of Finance and Administration, will host the call and webcast to discuss the financial results and provide an update on recent developments and clinical progress. Management will be available to answer questions live immediately following the earnings announcement and prepared remarks portion of the call.


To participate in the call and webcast, please refer to the information below:


Event: Fourth Quarter 2022 Earnings Conference Call and Business Update


Date: Tuesday, March 21, 2023


Time: 5:00 p.m. (EDT)


U.S. & Canada Dial-In: 877-407-0312


International Dial-In: +1 201-389-0899


Conference ID: 13736745


Webcast Link: https://www.webcast-eqs.com/navidbioph20230321/en


A live audio webcast of the conference call will also be available on the investor relations page of Navidea’s corporate website at www.navidea.com. In addition, the recorded conference call can be replayed and will be available for 90 days following the call on Navidea’s website.


About Navidea


Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its Manocept platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea’s Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company’s pipeline through global partnering and commercialization efforts. For more information, please visit www.navidea.com.




Forward-Looking Statements


This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business. Forward-looking statements include our expectations regarding pending litigation and other matters. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, among other things: our history of operating losses and uncertainty of future profitability; the final outcome of any pending litigation; our ability to successfully complete research and further development of our drug candidates; the timing, cost and uncertainty of obtaining regulatory approvals of our drug candidates; our ability to successfully commercialize our drug candidates; dependence on royalties and grant revenue; our ability to implement our growth strategy; anticipated trends in our business; our limited product line and distribution channels; advances in technologies and development of new competitive products; our ability to comply with the NYSE American continued listing standards; our ability to maintain effective internal control over financial reporting; the impact of the current coronavirus pandemic; and other risk factors detailed in our most recent Annual Report on Form 10-K and other SEC filings. You are urged to carefully review and consider the disclosures found in our SEC filings, which are available at http://www.sec.gov or at http://ir.navidea.com.


Investors are urged to consider statements that include the words “will,” “may,” “could,” “should,” “plan,” “continue,” “designed,” “goal,” “forecast,” “future,” “believe,” “intend,” “expect,” “anticipate,” “estimate,” “project,” and similar expressions, as well as the negatives of those words or other comparable words, to be uncertain forward-looking statements.


You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be incorrect. We undertake no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this report. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially from those anticipated or implied in the forward-looking statements.


Investor Relations Contact


Navidea Biopharmaceuticals, Inc.

Jeffrey Smith

Vice President of Operations











December 31,


December 31,










Cash and cash equivalents

  $ 1,995,860     $ 4,230,865  

Other current assets

    1,208,084       1,152,420  

Non-current assets

    1,167,662       1,261,548  

Total assets

  $ 4,371,606     $ 6,644,833  

Liabilities and stockholders' equity:


Current liabilities

  $ 9,941,889     $ 5,299,802  

Note payable to related party, net of discount

    1,871,715       -  

Deferred revenue, non-current

    700,000       700,000  

Other liabilities

    1,312       20,288  

Total liabilities

    12,514,916       6,020,090  

Navidea stockholders' (deficit) equity

    (8,435,828 )     (106,556 )

Noncontrolling interest

    292,518       731,299  

Total stockholders' equity

    (8,143,310 )     624,743  

Total liabilities and stockholders' equity

  $ 4,371,606     $ 6,644,833  






Three Months Ended


Twelve Months Ended


December 31,


December 31,


December 31,


December 31,

















  $ 610     $ 50,348     $ 65,652     $ 531,513  

Cost of revenue

    50,036       -       184,947       -  

Gross (loss) profit

    (49,426 )     50,348       (119,295 )     531,513  

Operating expenses:


Research and development

    1,890,113       1,372,314       5,969,774       5,141,910  

Selling, general and administrative

    1,258,681       2,317,285       7,961,826       7,450,015  

Total operating expenses

    3,148,794       3,689,599       13,931,600       12,591,925  

Loss from operations

    (3,198,220 )     (3,639,251 )     (14,050,895 )     (12,060,412 )

Other (expense) income:


Interest (expense) income, net

    (245,620 )     (1,938 )     (1,098,322 )     (6,361 )

Gain on extinguishment of debt

    -       -       -       366,000  

Other, net

    (38,788 )     (10,974 )     (27,939 )     (14,115 )

Loss before income taxes

    (3,482,628 )     (3,652,163 )     (15,177,156 )     (11,714,888 )

Provision for income taxes

    -       -       -       (16,043 )

Net loss

    (3,482,628 )     (3,652,163 )     (15,177,156 )     (11,730,931 )

Net (income) loss attributable to noncontrolling interest

    (1 )     -       3       4  

Net loss attributable to Navidea and subsidiaries

    (3,482,629 )     (3,652,163 )     (15,177,153 )     (11,730,927 )

Deemed dividend on preferred stock exchanged for Units

    -       -       (2,037,886 )     -  

Net loss attributable to common stockholders

  $ (3,482,629 )   $ (3,652,163 )   $ (17,215,039 )   $ (11,730,927 )

Loss attributable to common stockholders per common shares (basic and diluted)

  $ (0.11 )   $ (0.12 )   $ (0.56 )   $ (0.40 )

Weighted average shares outstanding (basic and diluted)

    32,376,900       30,161,825       30,901,869       29,343,542